Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A prospective case–control study of modest size (150 participants) with clear separation between groups and strong ROC performance for a candidate biomarker, but surrogate endpoints (AUC, survival association) rather than a clinical trial of intervention, requiring confirmation in independent cohorts.
This is a narrative review synthesizing mechanistic and preclinical evidence on CAF biology in osteosarcoma, proposing translational directions without clinical trial data or validated biomarkers.
This is a narrative review synthesizing mechanistic concepts and therapeutic rationales without reporting primary empirical findings, clinical trial data, or comparative evidence from original research.
A narrative review article proposing a conceptual framework that challenges the fibroblast-centric model of ECM remodeling; raises questions about non-fibroblast stromal contributions rather than testing or confirming a specific empirical claim.
This is a narrative review synthesizing mechanistic rationale and emerging evidence for a novel intervention; it raises questions about engineered probiotic consortia rather than reporting definitive efficacy data from controlled trials.
Preclinical in vitro and xenograft study proposing a mechanism by which an existing drug may enhance chemotherapy, without clinical efficacy data or human evidence.
Preclinical proof-of-concept in engineered cellular vesicles and mouse tumor models; no human data, no efficacy endpoint with confidence intervals or statistical comparison, and no toxicity data reported.
This is a systematic review of preclinical models (in vitro and ex vivo platforms) without primary efficacy data, clinical outcomes, or comparative effectiveness evidence; it maps landscape and provides catalogue value but does not establish whether any model predicts clinical benefit.